Loading...
•
Mar 31, 2022
Lianbio-Adr Q1 2022 Earnings Report
LianBio reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Key Takeaways
LianBio reported a net loss of $27.7 million for the first quarter of 2022, with research and development expenses at $12.3 million and general and administrative expenses at $16.1 million. The company's cash balance totaled $389.1 million, projected to fund operations through mid-2024.
Partner Bristol Myers Squibb received U.S. FDA approval of mavacamten for oHCM treatment.
Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM is ongoing.
Partner Tarsus announced positive topline data from the Phase 3 Saturn-2 clinical trial of TP-03 in patients with Demodex blepharitis.
Three additional pipeline programs are expected to enter Phase 3 clinical trials in China by year-end 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...